Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCM-181 injection in idiopathic pulmonary fibrosis (IPF)
CTR20243826Phase 2Active
- Sponsor
- Yunnan Shunxi Regenerative Medicine Engineering
- Start
- Oct 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of SCM-181 in idiopathic pulmonary fibrosis (IPF), sponsored by Yunnan Shunxi Regenerative Medicine Engineering. Started Oct 2024; status: active.
02
Drugs
SCM-181
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20243826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243826.